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The key regulator of the switch from latent to lytic replication of the human herpesvirus 8 (HHV-8; KSHV) is the replication and
transcription activator (Rta). The ability of Rta to regulate cellular gene expression was examined by transient transfection into cells
that were not infected with HHV-8. Rta induced some, but not all, NF-B-responsive reporters through mechanisms that did not
involve activation of classic forms of NF-B. Furthermore, transfection of the NF-B subunit Rel A inhibited the ability of Rta to
transactivate some but not all reporters. For example, Rel A inhibited the ability of Rta to transactivate the IL-6 promoter, but only
when sequences upstream of the NF-B site were present. The ability of Rel A to inhibit Rta-mediated transactivation was not
dependent on a functional NF-B site within the promoter, suggesting an indirect mechanism for inhibition. These studies suggest
that Rta expression during lytic reactivation of HHV-8 would lead to expression of some cellular genes, including IL-6, whereas
activation of NF-B could inhibit some responses to Rta. © 2002 Elsevier Science (USA)INTRODUCTION
Human herpesvirus 8 (HHV-8), also known as Kaposi’s
sarcoma-associated herpesvirus (KSHV), is etiologically as-
sociated with Kaposi’s sarcoma (KS), primary effusion lym-
phoma (PEL), and an AIDS-associated plasmablastic vari-
ant of multicentric Castleman’s disease (MCD) (Schulz,
2000). HHV-8 is a member of the gammaherpesvirus sub-
family and bears significant homology to Epstein–Barr virus
(EBV) and herpesvirus saimiri (Russo et al., 1996).
Herpesviruses establish two modes of infection, latent
and lytic, depending upon the cell type infected and other
physiological parameters (Roizman, 1996; Wagner, 1991).
Maintenance of episomal viral genomes, highly re-
stricted gene expression, and a lack of progeny produc-
tion characterize latency. During lytic, or productive in-
fection, gene expression proceeds through a temporally
regulated cascade leading to viral DNA replication and
the production of progeny virions. A key HHV-8 regulator
of the switch from a latent to lytic program is Rta (repli-
cation and transcription activator), also known as ORF 50
(Lukac et al., 1998, 1999; Sun et al., 1998), activator of
replication and transcription (ART) (Wang et al., 2001),
and Lyta (Sakakibara et al., 2001). Rta is encoded within
a bicistronic transcript containing five exons: a small 5
exon located upstream of open reading frame 49 (ORF
1 To whom correspondence and reprint requests should be ad-29349), which includes the initial coding sequences; a sec-
ond exon generated from ORF 50 encompasses the
remaining coding sequence of Rta; and three additional
exons corresponding to the KbZIP (ORF K8) transcript
(Lukac et al., 1999). The Rta protein is highly phosphor-
ylated and contains multiple domains including amino-
terminal basic and leucine zipper motifs and a carboxyl-
terminal transactivation domain (Lukac et al., 1999). Rta
induces the expression of a number of HHV-8 promoters
in both HHV-8-infected PEL cell lines and uninfected cell
lines (Gradoville et al., 2000; Lukac et al., 1999; Sun et al.,
1998) and is sufficient to drive the lytic program to prog-
eny virion production (Gradoville et al., 2000). Addition-
ally, expression of a dominant-negative Rta that lacks a
transactivation domain blocks HHV-8 lytic reactivation
induced by multiple stimuli (Lukac et al., 1999).
Several studies have begun to elucidate the mecha-
nisms involved in Rta-mediated gene induction. Se-
quences in the HHV-8 viral interferon regulatory factor-1
(vIRF-1) (Chen et al., 2000), ORF 57 (Lukac et al., 2001),
Rta (Sakakibara et al., 2001), and PAN (also known as
nut-1 or T1.1) (Song et al., 2001) promoters that are re-
sponsive to Rta have been identified. Recombinant Rta
directly binds to a palindromic sequence in the ORF 57
and K-bZIP (ORF K8) promoters (Lukac et al., 2001) and to
a distinct sequence in the PAN promoter (Song et al.,
2001), yet these sequences are not present in some
Rta-responsive promoters (Lukac et al., 2001). AlthoughKey Words: human herpesvirus 8; Kaposi’s sarcoma he
promoters; NF-B.
dressed at Winship Cancer Institute, 1365-B Clifton Road NE, Atlanta,
GA 30322. Fax: (404) 778-3965. E-mail: mofferm@emory.edu.
doi:10.1006/viro.2002.1582rus; Rta; ORF 50; transcription; lytic reactivation; cellular
recombinant Rta can bind to these sequences, Rta that is
present in nuclear extracts from PELs fails to bind to
0042-6822/02 $35.00rpesvi© 2002 Elsevier Science (USA)
All rights reserved.
these same sequences (Lukac et al., 2001; Song et al.,
2001). Cellular transcription factors have also been
shown to be involved in Rta-mediated transcription. For
example, Oct 1 has been shown to be important for
Rta-mediated transactivation of the Rta promoter. Rta
also binds to the coactivator CREB-binding protein (CBP),
leading to enhanced transactivation, whereas binding of
histone deacetylase (HDAC) by Rta suppresses its ability
to induce gene expression (Gwack et al., 2001a).
In this study, we sought to characterize the conse-
quences of Rta in the absence of HHV-8 infection on
non-HHV-8 viral and cellular promoters. We demonstrate
that (1) some but not all B-containing promoters were
activated by Rta; (2) Rta induction of NF-B-responsive
promoters was resistant to inhibition by IB and hence
was distinct from induction by the NF-B subunit Rel A;
(3) transfected Rta resulted in interleukin-6 (IL-6) pro-
moter activation and secretion of cellular IL-6; (4) multi-
ple cis elements, including activating transcription factor
(ATF), CAAT enhancer binding protein  (C/EBP), and
nuclear factor B (NF-B) sites were not essential for Rta
induction of the IL-6 promoter but contributed to respon-
siveness in some situations; (5) Rta induction of some,
but not all, promoters was inhibited by cotransfection of
Rel A; and (6) the ability of Rel A to inhibit Rta-mediated
transactivation of the IL-6 promoter was not dependent
on an intact NF-B-binding site. These data suggest that
induction of cellular genes by Rta may contribute to the
pathogenesis of HHV-8-associated diseases and that in
some situations NF-B modulates Rta responsiveness.
RESULTS
Rta induces some but not all NF-B-responsive
promoters
Since Rta is a potent activator of HHV-8 genes and has
been shown to interact with several cellular factors, we
were interested in examining the ability of Rta to induce
cellular or viral promoters in the absence of HHV-8-
derived sequences. We first examined the effects of Rta
on three heterologous promoter constructs (Fig. 1A): PR-
DII4-CAT, which contains four tandem NF-B responsive
elements (PRD II) from the interferon- promoter linked
to 128 to 20 of the -globin promoter (Fan and Ma-
niatis, 1989), as well as PRDI4-CAT and PRDIII6-CAT,
which have the B elements replaced with tandem IRF-
responsive elements from the interferon- promoter
linked to 128 to 20 of the -globin promoter (Fan and
Maniatis, 1989; Keller and Maniatis, 1988). Thus, these
reporter constructs have identical transcription start
sites and coding regions and differ only in the composi-
tion of the upstream PRD elements. PRDII4-CAT was
strongly activated by Rta, whereas PRDI4-CAT or PRDIII6-
CAT were minimally responsive with induction that was
comparable to that of induction of the -globin promoter
alone (Fig. 1B). These data indicate that the tandem
PRDII elements were responsive to induction by Rta,
whereas neither PRD I or PRD III were responsive.
To examine the mechanisms involved in the Rta re-
sponsiveness of the NF-B-responsive construct PRDII4-
CAT, we compared the induction by Rta to induction by
the NF-B subunit Rel A. Rta induced PRDII4-CAT to
levels comparable to that of the NF-B subunit Rel A (Fig.
1C). However, while the induction of PRDII4-CAT by Rel A
was strongly inhibited by cotransfection of IB, an in-
hibitor of NF-B, Rta induction of PRDII4-CAT was not
affected by IB (Fig. 1C). Thus, the mechanisms in-
volved in PRDII4-CAT induction by Rta and transfected
Rel A are at least in part distinct.
The ability of Rta to activate another NF-B-containing
construct, HIV(B)4-CAT, was then tested. HIV(B)4-CAT
was constructed from the HIV LTR through duplication of
tandem B elements and deletion of some elements,
including an Sp1 site (Kunsch et al., 1992). Thus, this
construct has multiple B elements, similar to PRDII4-
CAT, but also contains additional HIV elements. Although
the HIV B sequences (5-GGGGACTTTCC-3) differ
somewhat from the PRDII site (5GGGAAATTCC-3), both
are responsive to the NF-B subunit Rel A. While Rel A
strongly induced HIV(B)4-CAT, Rta did not induce CAT
activity from this construct (Fig. 2). Thus some, but not all,
NF-B-responsive promoters are inducible by Rta.
Rta induces the interleukin-6 promoter
To explore the effect of Rta on cellular promoters, we
examined the ability of Rta to induce 435 IL6-CAT, a
construct that contains 435 to 70 of the human IL-6
promoter (Fig. 3A). In 293T cells, cotransfection of Rta
and 435 IL6-CAT resulted in a large induction of CAT
activity (Fig. 3B). This induction was also observed using
a nontagged Rta construct, pcDNA-FLc50, but not with
mutant Rta lacking the carboxyl-terminal transactivation
domain, pCMV-myc-nuc-50STAD (data not shown).
A number of cis elements involved in IL-6 promoter
induction have been identified: AP-1 (283 to 277),
IRF-1 (267 to 254), ATF (163 to 158), C/EBP
(154 to 146; 83 to 75), Sp-1 (126 to 101), as
well as NF-B sites (75 to 63) (Fig. 3A) (Akira and
Kishimoto, 1997; Faggioli et al., 1997; Sanceau et al.,
1995). There are also numerous glucocorticoid response
elements (GRE) (Ray et al., 1990), a putative retinoblas-
toma control element (RCE) (Ray et al., 1990; Takeshita et
al., 2000), and an RBPJ-binding site (Kannabiran et al.,
1997; Palmieri et al., 1999; Plaisance et al., 1997) that
function in negative regulation of the IL-6 promoter.
IL-6 promoter deletion constructs were used to identify
regions of the IL-6 promoter important in Rta responsive-
ness. Deletion of the IL-6 promoter to 227, which de-
leted the AP-1 and IRF-1 sites, resulted in a 41% reduc-
tion in Rta-induced CAT activity compared to Rta induc-
tion of 435 IL-6 CAT (Fig. 3B). Deletion to 160, which
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deletes the GRE and ATF sites, decreased Rta induction
by 63%, whereas deletion to 130 IL-6 CAT, which re-
moves the 5C/EBP site as well as the other upstream
elements, restored Rta responsiveness to levels that
were comparable to that of 435 IL-6 CAT. Rta induction
of 100 IL-6-CAT, which lacks the putative retinoblas-
FIG. 1. Rta transactivates PRDII4-CAT through a mechanism that is not inhibited by IB. (A) Diagram of reporter constructs. The 128-CAT
contains 128 to 20 of the -globin promoter and is a common element for all constructs. The remaining constructs represent tandem copies of
PRD I, II, and III elements from the IFN promoter linked to 128 CAT, as illustrated. (B) 293T cells were transfected with the indicated CAT reporter
construct and pEF-LacZ along with vector () or pcDNA-FLAG-ORF 50 (Rta) (). Seventy-two hours posttransfection, lysates were harvested and
assayed for CAT and -galactosidase (-gal) activity. CAT activity was standardized to -gal to correct for differences in transfection efficiencies. This
representative graph depicts relative CAT activity and standard deviation of triplicate samples. Cpm/-gal for all samples are compared to that of
Rta-induction of PRDII4-CAT, which is set at 100%. (C) PRDII4-CAT and expression vectors for Rta (pcDNA-FLAG-ORF 50), the NF-B subunit Rel A
(pCMV-p65), or IB (pCMV-IB) were transfected into 293T cells as described under Materials and Methods, and CAT activity was measured at
72 h posttransfection. Cpm/-gal for all samples are compared to that of Rta-induction of PRDII4-CAT, which is set at 100%.
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toma control element and an Sp1 site, was 66% less than
that of 435 IL-6 CAT, although significant levels of CAT
activity were still induced. When the IL-6 promoter was
truncated to 52, which deletes the 3C/EBP and the
NF-B elements, Rta responsiveness of the promoter
was abolished. Thus, sequences between 100 and
52 are critical for Rta induction of IL-6-CAT, whereas
sequences upstream of 100 were not essential.
Changes in the level of promoter activity resulting from
serial deletion of promoter elements suggested the pres-
ence of elements that both positively and negatively af-
fected induction by Rta. The 130 IL-6 CAT construct that
lacked the 5C/EBP and ATF elements was as responsive
to Rta as the435 IL-6 CAT, indicating that neither element
was required for Rta responsiveness. Deletion to 52 IL-6
CAT led to complete loss of responsiveness to Rta, sug-
gesting that the NF-B element might be required for Rta
responsiveness, but other elements were also lost in this
construct. Mutational analysis was therefore used to ex-
plore the role of specific sites in Rta responsiveness. The
NF-B, ATF, and 5C/EBP sites have been shown to be
important in induction of IL-6 by other inducers (Harcourt
and Offermann, 2000; Hu et al., 2000; Vanden Berghe et
al., 2000) and were examined for their role in Rta respon-
siveness. Rta was cotransfected with wild-type 435
IL6-CAT or with 435 IL6-CAT constructs containing mu-
tations in the indicated sites (Fig. 4A), and CAT activity
was assessed 72 h posttransfection. Mutation of either
the ATF or the 5 C/EBP sites in 435 IL6-CAT resulted
in a modest decrease in induction of CAT activity by Rta,
and mutations in both sites reduced but did not eliminate
Rta responsiveness (Fig. 4B). Mutation of the NF-B site
in 435 IL6-CAT reduced but did not eliminate activity,
and the reduction was less than the reduction that oc-
curred when both the ATF and the C/EBP sites were
mutated. Thus, none of these sites were required for Rta
responsiveness, yet mutation of each of these sites de-
creased the level of induction.
The NF-B subunit Rel A and Rta activate the IL-6
promoter in distinct ways and functionally interact
through mechanisms involving promoter sequences
upstream of the NF-B site
The 100 IL-6 CAT construct that was responsive to
Rta contains a NF-B site but lacks multiple known
FIG. 2. Rta does not activate HIV(B)4-CAT. (A) Diagram of HIV(B)4-CAT. (B) 293T cells were transfected with HIV(B)4-CAT and pEF-LacZ along
with control, pcDNA-FLAG-ORF 50 (Rta), or pCMV-p65 (Rel A). CAT activity is expressed as a percentage of Rel A-induced activity (defined as 100%).
This representative graph depicts the mean  standard deviation of triplicate samples.
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positive regulatory elements, including the ATF and 5
CEBP/ sites. To determine whether elimination of these
upstream elements increased the need for an intact
NF-B site for Rta responsiveness, 100 IL6-CAT con-
structs containing either wild-type or mutated NF-B site
were cotransfected with Rta into 293T cells, and CAT
activity was assessed 72 h posttransfection. Rta induced
100 IL6-CAT containing the intact NF-B site, whereas
mutation of the NF-B completely abolished activation by
Rta (Fig. 5A), indicating that the NF-B site was neces-
sary when upstream elements were missing.
We showed that Rta specifically induced the NF-B-
responsive construct PRDII4-CAT, but that this induction
was not inhibited by IB (Fig. 1C). This suggests that
Rta and NF-B may activate transcription in part through
the same consensus element but through different
mechanisms. To compare the induction of IL6-CAT by Rta
and Rel A, we cotransfected IL6-CAT reporter constructs
with Rta, Rel A, and IB, individually and in combina-
tion, into 293T cells. 100 IL6-CAT construct was re-
sponsive to either Rta or Rel A individually (Fig. 5B).
Similar to induction of PRDII4-CAT, IB had no effect on
Rta induction of 100 IL6-CAT, whereas induction by Rel
A was completely inhibited by IB. Cotransfection of
Rta and Rel A led to levels of reporter activity that were
comparable to that of Rta alone. Thus, Rta induction of
100 IL6-CAT was dependent upon the NF-B sequence
but was not mediated by a factor that is inhibitable by
transfected IB.
When responsiveness to Rta and Rel A was compared
using the 435 IL6-CAT reporter, Rta induced CAT activ-
ity, but Rel A was insufficient (Fig. 5C). Intriguingly, co-
transfection of Rel A together with Rta greatly diminished
Rta-mediated induction, whereas IB did not inhibit Rta
induction of 435 IL6-CAT (Fig. 5C). Thus, functional
interactions between Rta and Rel A were apparent when
sequences between 435 and 100 were present (Fig.
5C) but not in their absence (Fig. 5B). These data indicate
that IL-6 promoter sequences upstream of 100, and
thus upstream of the NF-B site, are involved in the
inhibition of Rta-mediated activation by the NF-B sub-
unit Rel A.
Since Rel A inhibited the ability of Rta to transactivate
the IL-6 promoter only when sequences upstream of the
FIG. 3.Multiple upstream elements affect the level of interleukin 6 promoter-CAT activity in response to transfected Rta. (A) Diagram of the IL6-CAT
truncation constructs. AP-1, activating protein-1; IRF-1, interferon regulatory factor-1; GRE, glucocorticoid response element; ATF, activating transcrip-
tion factor; C/EBP, CAAT enhancer-binding protein; RCE, retinoblastoma control element; Sp1, stimulating protein 1; NF-B, nuclear factor B; TATA,
TATA box. (B) Transient reporter assays with the indicated IL6-CAT constructs in the absence and presence of transfected Rta were performed in 293T
cells as described in the legend to Fig. 1B. Rta induction of wild-type 435 IL6-CAT was defined as 100%.
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NF-B site were present, this raised the possibility that
the inhibition was not a consequence of the interaction
of Rel A with the NF-B site. To test this possibility,
responsiveness was assessed using435 IL-6 CAT with
a mutant NF-B-binding site. Rta effectively induced CAT
activity in the absence of Rel A, whereas Rel A was
unable to induce reporter activity (Fig. 5D). Cotransfec-
tion of Rel A with Rta inhibited the ability of Rta to induce
reporter activity with the mutant NF-B site in 435 IL-6
CAT. Thus, the inhibition of Rta-mediated induction of the
IL-6 promoter by Rel A was not dependent on interaction
of Rel A with the NF-B site of the IL-6 promoter.
Rta and the NF-B subunit Rel A both activate IL6-
CAT in HeLa cells through mechanisms involving
multiple cis elements
HeLa cells were used to compare Rel A and Rta
induction of wild-type and mutant 435 IL6-CAT con-
structs since transactivation of 435 IL-6 CAT by Rel A
could not be detected in 293T cells. Transfection of a Rel
A expression vector activated 435 IL6-CAT to levels
about 50% that of Rta under the same conditions (Fig. 6).
Dual mutation of the ATF and 5C/EBP sites eliminated
responsiveness to Rel A, whereas the mutant reporter
responded to Rta with about 20% of the activity seen with
the wild-type 435 IL-6 CAT reporter. As expected, mu-
tation of the NF-B site eliminated responsiveness to Rel
A, whereas responsiveness to Rta was maintained at
about 60% of the level seen with the wild-type 435 IL-6
CAT reporter. Thus, promoter elements that were essen-
tial for responsiveness to Rel A were not essential for
responsiveness to Rta.
Rta induces secreted IL-6 protein in 293T cells
To determine whether Rta induces secretion of cellular
IL-6 protein, an Rta expression construct was transfected
into 293T cells, and levels of IL-6 in the medium were
assayed at 72 h posttransfection (Fig. 7). Rta induced a
dose-dependent increase in secreted IL-6 protein which
reached levels that were fourfold higher than in medium
from untransfected cells or cells transfected with empty
vector. Transfection of a Rel A expression construct in-
duced a twofold increase in secreted cellular IL-6. Thus,
Rta induced secretion of IL-6 protein, which was consis-
tent with Rta-dependent IL-6 promoter activation in 293T
cells.
FIG. 4. Rta induces 435 IL-6 CAT reporters despite mutations in the NF-B site and other consensus elements. (A) Diagram of the wild-type and
mutant 435 IL6-CAT constructs: The specific nucleotides that were mutated are underlined. (B) Transient reporter assays were performed in 293T
cells with the indicated wild-type and mutant IL6-CAT constructs in the absence and presence of transfected Rta. The level of CAT activity resulting
from Rta using the wild-type 435 IL6-CAT was defined as 100%.
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DISCUSSION
The data presented here broaden our understanding
of the possible consequences of Rta expression. We
demonstrate that Rta can profoundly affect the function
of several cellular promoters in the absence of other
HHV-8 factors. Furthermore, the Rel A subunit of NF-B
can inhibit Rta-mediated transactivation of some, but not
all, promoters. This suggests that factors that activate
NF-B could suppress the ability of Rta to induce some
cellular and viral genes, thereby modulating the conse-
quences of lytic reactivation.
The ability of Rta to transactivate some NF-B respon-
sive promoters is not likely to be through activation of
NF-B by Rta. We found that the responsiveness of PR-
DII4-CAT was dependent on sequences that are respon-
sive to NF-B, yet the induction by Rta was not inhibited
by IB and thus was distinct from the induction by Rel
A. The NF-B family of transcription factors includes
factors in addition to Rel A that can regulate transcrip-
tion, yet all known transactivating forms of NF-B are
inhibited by IB (Ghosh et al., 1998). Furthermore, Rel A
inhibited the ability of Rta to transactivate several report-
ers, including the IL-6 promoter. Such an inhibition would
not have occurred if Rta were inducing these promoters
through activation of NF-B.
The transactivation of IL-6 by Rta differs considerably
from the transactivation by many other characterized
activators. IL-6 is induced in response to a variety of
different factors, including IL-1, TNF, lipopolysaccha-
ride, and double-stranded RNA (Akira et al., 1992; Akira
and Kishimoto, 1997; Dendorfer et al., 1994; Harcourt and
Offermann, 2001; Hu et al., 2000; Ray et al., 1989). The
ATF/CREB and the C/EBP-binding sites are found
within two overlapping regions that confer responsive-
ness to a variety of stimuli, including forskolin, TPA,
IL-1, TNF, and LPS (Akira et al., 1992; Dendorfer et al.,
1994; Harcourt and Offermann, 2000; Hu et al., 2000;
Vanden Berghe et al., 2000). These regions are referred
to as “multiple cytokine and second messenger response
elements (MREs)” and are located between 173 and
145 (Dendorfer et al., 1994; Ray et al., 1990). Our data
demonstrate that this region is not required for respon-
siveness to Rta since the 130 IL-6 CAT construct that
lacks this region is as responsive to Rta as larger con-
structs that contain this region. Furthermore, the NF-B
site that is located at 73 to 63 has been shown to be
critical for responsiveness to a variety of stimuli, includ-
ing IL-1, TNF, and dsRNA (Harcourt and Offermann,
2000), yet it is not essential for responsiveness to Rta if
upstream sequences are present. For example, the
NF-B site was not required for Rta responsiveness in
the435 IL-6 CAT construct, whereas it was required for
Rta responsiveness using 100 IL-6 CAT.
Our studies demonstrate that some promoter con-
structs lacking the ATF and C/EBP-binding sites were
as responsive to Rta as constructs containing these
sites, yet these sites appeared to contribute to Rta re-
sponsiveness when other upstream elements were
present. This was shown by dual mutation of the ATF and
FIG. 5. Rel A inhibits Rta-mediated transactivation of the IL-6 pro-
moter when elements upstream of the B site are present. (A) 293T
cells were transfected with either wild-type 100 IL6-CAT or mutant
B-100 IL6-CAT with or without cotransfected Rta. The level of CAT
activity resulting from Rta using the wild-type 100 IL6-CAT was de-
fined as 100%. (B) 293T cells were transfected with wild-type 100
IL6-CAT and with expression vectors for Rta, Rel A, and/or IB, as
indicated. The level of CAT activity resulting from Rta was defined as
100%. (C) 293T cells were transfected with 435 IL6-CAT and with
expression vectors for Rta, Rel A, and/or IB, as indicated. The level
of CAT activity resulting from Rta was defined as 100%. (D) 293T cells
were transfected with 435 IL6-CAT that contained a mutated NF-B
site, and cells were cotransfected with expression vectors for Rta and
Rel A as indicated. The level of CAT activity resulting from Rta was
defined as 100%.
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C/EBP sites in the 435 IL6-CAT constructs, where
responsiveness to Rta was reduced by 80%. These same
mutations completely eliminated responsiveness to Rel
A. We have previously shown that HeLa cells transfected
with the 435 IL-6 CAT construct containing dual muta-
tion of the ATF and C/EBP sites were unresponsive to
either IL-1 or to double-stranded RNA, whereas high
levels of promoter activity occurred using wild-type435
IL-6 CAT (Harcourt and Offermann, 2000). The greater
importance of these sites in the Rta responsiveness with
the 435 IL6 CAT construct than in deletion constructs
suggests that their role is dependent on the context of
cis elements and interactions with other proteins.
The mechanism by which Rta induces transcription of
the PRDII4-CAT and IL6-CAT reporters is currently not
known. Rta affects gene expression through direct inter-
actions with DNA (Lukac et al., 2001; Song et al., 2001),
interactions with cellular transcription factors (Sakak-
ibara et al., 2001), interactions with coactivator proteins
(Gwack et al., 2001a,b), and alterations of signal trans-
duction cascades (Gwack et al., 2002). Neither PRDII4-
CAT nor IL6-CAT contains consensus elements that re-
semble known elements that directly bind Rta, including
a 31-bp sequence identified in the PAN promoter (Song
et al., 2001) and a distinct 12-bp palindromic sequence
that is found in the promoters for ORF 57 and k-bZIP
(Lukac et al., 2001). While these consensus elements
confer Rta responsiveness to heterologous promoters,
not all Rta-responsive genes contain these elements.
These consensus elements directly bind Rta expressed
from a bacterial or baculovirus system, yet they do not
bind Rta from nuclear extracts of TPA-induced BCBL-1
cells (Lukac et al., 2001; Song et al., 2001). This suggests
that Rta in nuclear extracts does not maintain the ability
to directly bind to its consensus elements, thereby com-
plicating the study of interactions between Rta and DNA.
Rta has been shown to cooperate with Oct-1 in activating
a heterologous promoter containing the Oct-1-binding
site (Sakakibara et al., 2001), but neither PRDII4-CAT nor
IL6-CAT contain Oct-1 sites. AP1 sites have been shown
to contribute to Rta responsiveness in the vIRF-1 pro-
moter through unknown mechanisms (Chen et al., 2000),
but our deletion analysis demonstrated that the AP1 site
of the IL-6 promoter was not critical for Rta responsive-
ness. Rta was recently reported to physically associate
with Stat 3 and induce dimerization independent of phos-
phorylation, leading to a transcriptionally active form of
Stat 3 (Gwack et al., 2002). One would predict that if a
comparable mechanism were involved in the Rta-medi-
ated transcription of IL-6-CAT, then a well-defined con-
sensus element would be required for Rta responsive-
ness. We did not find evidence of a critical element
required for Rta induction of the IL-6 promoter. Our data
demonstrated that multiple combinations of elements in
the IL-6 promoter contributed to Rta responsiveness. The
binding of the transcriptional coactivator CBP by Rta has
FIG. 6. Mutations in 435 IL6-CAT fully block transactivation by Rel A but not by Rta in HeLa cells. Reporter assays were done in HeLa cells using
wild-type or mutant 435 IL6-CAT constructs. The transfections were done using the same procedure as described for the 293T cells with
standardization to -gal as described in Fig. 1. The level of CAT activity resulting from Rta using the wild-type 435 IL6-CAT was defined as 100%.
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been shown to enhance Rta-mediated transactivation
(Gwack et al., 2001a). Transcription factors that bind CBP
could either enhance or repress Rta-dependent tran-
scription, depending on whether the protein becomes
part of the Rta complex or whether it competes with Rta
for the CBP. For example, the CBP-binding proteins c-jun
and adenovirus E1A had opposite effects on Rta-medi-
ated transcription, with c-jun enhancing Rta-mediated
transactivation and E1A repressing Rta-mediated trans-
activation (Gwack et al., 2001a). Two distinct regions of
CBP interact with various cellular proteins, with both
sites capable of binding to Rta. In addition, domains
within both the amino and the carboxyl-terminal regions
of Rta can bind to CBP. If the IL-6 promoter was bound by
a protein that interacts with one of the CBP domains,
then Rta might interact with the other protein-binding
domain of CBP. This would allow both CBP and Rta to
assemble at the IL-6 promoter in complexes that include
cellular DNA-binding proteins. Whether this or other
mechanisms are responsible for the observed re-
sponses remains to be determined.
The multiple mechanisms by which Rta affects gene
expression is reminiscent of the processes affected by
its homolog in Epstein–Barr virus, the BRLF1 gene prod-
uct Rta (Lukac et al., 1998; Sun et al., 1998). EBV-encoded
Rta directly binds a GC-rich DNA motif (Gruffat and
Sergeant, 1994) but also physically interacts with the
retinoblastoma protein (Rb) (Zacny et al., 1998), thereby
activating the transcription factors E2F (Swenson et al.,
1999). Additionally, EBV-encoded Rta activates the p38
and c-Jun N-terminal kinases, resulting in the phosphor-
ylation and activation of the cellular transcription factor
ATF2 (Adamson et al., 2000).
The mechanism by which Rel A inhibits Rta-mediated
transactivation is not known. The ability of Rel A to inhibit
Rta-mediated transactivation was dependent on se-
quences upstream of the NF-B site. The 435 IL6-CAT
was responsive to Rta but not to Rel A, yet in combina-
tion, Rel A blocked Rta induction of this construct. The
inhibition of Rta-mediated transaction was not a conse-
quence of competition for binding to the NF-B site since
the inhibition persisted when the NF-B site in the 435
IL6-CAT construct was mutated. One possibility is that
Rel A sequestered CBP, making it unavailable for Rta-
mediated transactivation. CBP is physiologically main-
tained at a limiting concentration in a variety of cells
(Kamei et al., 1996), and some CBP-binding proteins such
as adenovirus E1A have been shown to inhibit Rta-
mediated transactivation. NF-B requires CBP for activity
(Hottiger and Nabel, 2000; Sheppard et al., 1999), and
sequestration of CBP by NF-B would not require a
functional NF-B site to inhibit Rta-mediated transcrip-
tion. When the IL-6 promoter sequences upstream of the
NF-B site were deleted, there was no longer clear
evidence of inhibition of Rta-mediated induction by Rel A.
Since the truncated promoter was also responsive to Rel
A, it is possible that the observed activity resulted from
Rel A. Alternatively, the inhibition of Rta transactivation by
Rel A required sequences that were lacking in the 100
IL6-CAT construct.
The ability of Rel A to inhibit Rta-mediated transcrip-
tion extends to viral promoters. For example, we found
that Rel A inhibited transactivation of the vIRF-1 promoter
by Rta (F. Roan, N. Inoue, and M. K. Offermann, unpub-
lished data), and other investigators have found that Rel
A inhibits Rta-dependent induction of the HHV-8 PAN
promoter as well as its own promoter (H. J. Brown and R.
Sun, personal communication).
Cellular gene expression resulting from Rta might con-
tribute to the pathogenesis of diseases associated with
HHV-8. We have shown that Rta is sufficient to induce
IL-6 secretion. IL-6 is overexpressed in Kaposi’s sar-
coma, primary effusion lymphoma, and Castleman’s dis-
ease and can act as an autocrine or paracrine growth
factor (Aoki et al., 2001; Dourado et al., 1997; Drexler et
al., 1999; Foussat et al., 1999; Miles et al., 1990; Oksen-
hendler et al., 2000). Considerable lytic replication is
present in Castleman’s disease, whereas HHV-8 is pri-
marily latent in both KS and PEL (Dupin et al., 1999; Judde
et al., 2000; Sturzl et al., 1997). Cytokines such as TNF
and IL-1 that induce IL-6 expression are present in
many KS lesions (Oxholm et al., 1989), indicating that
factors independent of Rta are likely to contribute to the
high levels of IL-6 that occur. Nonetheless, the ability of
Rta to induce cellular genes might be of importance in
some of the changes that result during lytic replication.
FIG. 7. Rta induces secretion of IL-6 protein in 293T cells. 293T cells
were transfected with the indicated amounts of pcDNA-FLAG-ORF 50
(Rta) or pCMV-p65 (Rel A), equalized to 4 g with pcDNA3.1. Media
was removed 72 h after transfection and assayed for human IL-6 by
chemiluminescent ELISA using a standard curve with known concen-
trations of recombinant IL-6. This representative graph depicts the
average secreted cellular IL-6 pg/ml and standard deviation of dupli-
cate samples.
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The high levels of TNF and IL-1 that are expressed in
KS lesions would be expected to activate the transcrip-
tion factor NF-B. It is intriguing to speculate whether
activated NF-B could suppress the response to Rta in
KS lesions, thereby helping to maintain HHV-8 in the
latent state.
MATERIALS AND METHODS
Cell culture
293T and HeLa cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (Mediatech, Herdon, VA)
and MEM (Mediatech), respectively, supplemented with
10% fetal bovine serum (HyClone, Logan, UT), 5 mM
L-glutamine (Gibco-BRL, Rockville, MD), and 100 U/ml
penicillin-streptomycin (Gibco-BRL).
Plasmid constructs
pCMV-p65, pCMV-IB, and HIV(B)4-CAT were kindly
provided by Charles Kunsch and have been described
previously (Kunsch et al., 1992; Ruben et al., 1992). The
reporter constructs 128 -CAT, PRDI4-CAT, PRDII4-CAT,
and PRDIII6-CAT were provided by Tom Maniatis and
also have been described previously (Fan and Maniatis,
1989; Keller and Maniatis, 1988). The deletion constructs
of the IL-6 promoter and the 435 IL6-CAT constructs
containing mutations in the ATF, C/EBP, and/or NF-B
sites were described previously (Harcourt and Offer-
mann, 2000). The construct 100 mutB IL6-CAT was
generated in two steps. First, the appropriate region from
435 mutB IL6-CAT was PCR amplified and cloned into
pGEM-T easy (Promega, Madison, WI) to generate 100
mutB-TE. Next the SacI-NcoI fragment from 100
mutB-TE was cloned into the corresponding sites of
pCAT3-Basic. The construct was confirmed by sequenc-
ing (Emory DNA Sequencing Core Facility).
To generate an expression vector for Rta, exon 2 of Rta
was PCR amplified from BC-1 DNA using the primers
5-TCCCCGGGTAAGAAGCTTCGGCGGTCCTGT-3 and
5-CCGAATTCTGTAGGTTAACTCCACTTTGCACC-3. This
PCR product was digested with SmaI and EcoRI and
cloned into pBluescript II KS (Stratagene, La Jolla, CA)
to generate the plasmid pBS-ORF50B. A small DNA frag-
ment containing a BamHI site, a Kozak consensus se-
quence, an amino-terminal FLAG tag, and exon 1 of Rta,
which is located upstream of ORF 49, was generated by
annealing two oligonucleotides, 5-GATCCACCATGGAT-
TACAAGGATGACGACGATAAGATGGCGCAAGATGA-
CAA-3 and 5-TTGTCATCTTGCGCCATCTTATCGTCGTC-
ATCCTTGTAATCCATGGTG-3. The complete FLAG-tagged
Rta coding region was generated by cloning the exon 1
fragment between the BamHI and SmaI sites of pBS-
ORF50B. The Rta-coding region was then excised with
NotI and EcoRI and cloned into pCMV-Script (Strat-
agene). pcDNA-FLAG-ORF 50 was generated by sub-
cloning the tagged Rta coding region into the XbaI and
EcoRI sites of pcDNA3.1 (Promega). A nontagged Rta
expression vector, pCMV-FLc50, and an expression vec-
tor for a Rta truncation lacking the transactivation domain
(pCMV-myc-nuc-50STAD) were generously provided by
Don Ganem and were previously described (Lukac et al.,
1999).
Transfections and reporter assays
293T cells were split to six-well plates approximately
24 h prior to transfection and transfected at 50 to 70%
confluency using FuGENE 6 (Roche, Indianapolis, IN)
according to the manufacturer’s protocol. Transfections
for enzyme-linked immunosorbent assays (ELISAs) con-
sisted of 2 or 4 g of pcDNA-FLAG-ORF 50 or pCMV-p65,
equalized to 4 g with pcDNA3.1. DNA mixtures for
transfections for reporter assays contained 0.9 g of CAT
reporter plasmid, and 0.25 or 0.75 g of expression
vectors for transcription factors (e.g., Rta or Rel A) or
inhibitors (e.g., IB), respectively. In transfections for
reporter assays, 0.1 g of pEF-LacZ, a plasmid express-
ing -galactosidase under the control of the eukaryotic
elongation factor-1 promoter, was added and used as
an internal control for transfection efficiencies, and total
amounts of DNA were equalized to 2 g using pcDNA
3.1. Cells were harvested 24–72 h after transfection
and assayed for CAT and -galactosidase activity. Crude
lysates for reporter assays were obtained by lysis of the
cells using reporter lysis buffer (Promega) according to
the manufacturer’s instructions.
-galactosidase activity was measured on a LUMIstar
Galaxy luminometer (BMG Biotechnologies, Durham,
NC) using the Galacto-Light Plus chemiluminescent re-
porter gene assay system, according to the manufactur-
er’s instructions (Applied Biosystems, Bedford, MA).
-galactosidase activity in the lysates was determined
based on a standard curve generated using recombinant
-galactosidase (Promega). Chloramphenicol acetyl
transferase (CAT) activity was determined by phase ex-
traction of butyrylated [14C]chloramphenicol (Amersham-
Pharmacia, Piscataway, NJ) followed by scintillation
counting as previously described (Kingston and Sheen,
1997). Adjusted CAT activity was then obtained by nor-
malizing to relative levels of -galactosidase to correct
for differences in transfection efficiencies. Results were
obtained as mean  standard deviation from experi-
ments performed in triplicate.
IL-6 ELISA assays
Medium was taken from transfected 293T cells and
assayed for human interleukin-6 with the ImmuLux hu-
man IL-6 chemiluminescent ELISA, using monoclonal
antibodies, according to the manufacturer’s instructions
(Pierce Endogen, Rockford, IL).
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